



Gary Schwartz, MD
 Co-Chair for Experimental Therapeutics Committee
 Columbia University
 177 Fort Washington Avenue, Suite 6GN-435
 New York, NY 10032
 Phone: 212-305-2055
 Email: Schwartzg@columbia.edu

Charles Erlichman, MD, FRCPC, FACP
 Co-Chair for Experimental Therapeutics Committee
 Mayo Clinic
 200 First Street SW
 Rochester, MN 55905
 Phone: 507-266-3200
 Email: Erlichman.charles@mayo.edu

Date: April 23, 2015

To: Experimental Therapeutics Committee

From: Gary Schwartz, M.D.
 Charles Erlichman, M.D.

Re: **Experimental Therapeutics Committee Meeting**

Date: **Friday, May 15, 2015**

Time: **7:00am-10:00am Central**

Location: Loews Chicago O'Hare - Rosemont, IL 60018
 Room Louvre 3

Call In Information: (800) 501-8979 / 8087368

AGENDA

1. Status update on activated current trials: *Horvath*

a.	A091104 (permanently closed to enrollment)	A Phase II Study of MK-2206 in Patients with Progressing Recurrent/Metastatic Adenoid Cystic Carcinoma	A. Ho
b.	A091103 (permanently closed to accrual)	Phase II Study of the Angiopoietin -1 and -2 peptibody AMG386 for the Treatment of Angiosarcoma	S. D'Angelo
c.	A091102 (suspended to accrual)	Phase II Study of MLN8237 in Advanced Metastatic Sarcoma	M. Dickson
d.	A091101	Carboplatin-paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) – A Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck	J. de Souza

e.	N0871 (permanently closed to enrollment)	A Phase II Study of Carbopatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients with Measurable Disease with Cancer of Unknown Primary (CUP)	M. Goetz
f.	N0879 (permanently closed to enrollment)	A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma	R. McWilliams
g.	N1153 (suspended to accrual)	Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC	M. Borad
h.	A091201 (suspended to accrual)	Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma	J. Luke
i.	A091105	A Phase III Double Blind Randomized, Placebo Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)	M. Gounder
j.	A091305	A Phase 2 Randomized Study of Efatutazone, an Oral PPAR Agonist, in Combination with Paclitaxel versus Paclitaxel in Patients with Advanced Anaplastic Thyroid Cancer	R. Smallridge
k.	A091302	Randomized Phase II study of Sorafenib With or Without Everolimus in Patients with Radioactive Iodine Refractory Hürthle Cell Thyroid Cancer	E. Sherman
l.	A091202	A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma	M. Pishvaian

2. Status update on current trials in development: *Schwartz or Horvath*

a.	A091304	A Phase I/Randomized Phase II Study of MLN-0128 vs. Pazopanib in Patients with Advanced/Unresectable and/or Metastatic Sarcoma	W. Tap
b.	A091401	Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma	S. D'Angelo

3. Status of Concepts: *Schwartz or Horvath*

a.	Randomized Phase 2 Study of Chemo and Androgen Ablation in Salivary Gland Cancer EORTC 1206/A091306		A. Ho
b.	A Phase II Study of Enzalutamide for Patients with Androgen Receptor Positive Salivary Cancers (A091404)		A. Ho
c.	A Phase II Study of Cetuximab and Lapatinib in Patients with Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (A091501)		J. Deeken
d.	B Smart		E. Horvath
e.	Reversing Resistance to Pazopanib with Histone Deacetylase Inhibition		P. Munster

4. Update on NCI sponsored Match - *Schwartz*

5. Alliance Operations Update - *Horvath*

- International Affairs
- Accrual Initiatives
- Pharmaceutical and Regulatory Affair